Resources Top 5: DY6 goes through the roof after identifying gallium in Malawi
Andromeda Metals had a stellar rise after delivering its quarterly report for the three months ending March 31
Investors in Alkane Resources continue to support the merger arrangements with shares up another 10.26%
Your standout small cap resources stocks for Tuesday, April 29, 2025
DY6 Metals (ASX:DY6)
After revealing the presence of high-value critical mineral gallium at the Tundulu REE and phosphate project in Malawi, DY6 Metals has gone through the roof, increasing 340% to a daily high of 18.5c.
A new look at old drill data uncovered high-grade gallium from surface with some assays showing impressive grades over long stretches, including up to 74 metres at more than 93 g/t gallium with a spike at 310 g/t.
The review uncovered notable intersections:
74m at 93.26g/t gallium oxide and 1.56% total rare earth oxides from 72m including 14m at 202.79g/t Ga2O3 from 89m;
53m at 72.79g/t Ga2O3 and 1.02% TREO from surface including 12m at 145.07g/t Ga2O3 from 25m; and
30m at 94.63g/t Ga2O3 and 4.03% TREO from surface.
The gallium mineralisation is open at depth as while some of the elevated results occurred within the saprolite clays, others occurred deeper within fresh rock with no assaying done for deeper potential.
There is also plenty of room for more mineralisation to be found as just 40% of the highly prospective area around the Nathace and Tundulu hills target areas have been drill-tested.
Should the company establish the presence of significant gallium, it could add a valuable byproduct to the already heady product mix at Tundulu.
The 91.5km2 Tundulu project comprises several hills in a ring around a central vent called Nathace Hill, where the majority of historical surface sampling and drilling has been undertaken and identified heavy REE mineralisation.
Gallium intersections were noted in 27.7% of the 4901 samples from historical diamond and reverse circulation drilling carried out in 2014 that the company assayed for the critical mineral.
Data indicates there is a positive relationship between the gallium and TREO mineralisation though the trend lines suggest that further research on the relative contents of individual lithologies is required.
DY6 Metals (ASX:DY6) has commissioned Auralia Metallurgy to conduct preliminary metallurgical testwork on a select bulk sample from Tundulu to determine the deposit's suitability to produce a separate rare earth and phosphate concentrate.
Early signs point to a potentially serious play and the market will be watching closely when results land in the coming weeks.
Gallium is hot property thanks to demand in electronics and semiconductors, and most of the global supply is stitched up by China.
Prices have risen steadily in recent years due to growing demand but supply security has been eroded significantly by export restrictions placed by dominant producer China.
Andromeda Metals (ASX:ADN)
Kaolin-focused Andromeda Metals had a stellar rise after delivering its quarterly report for the three months ending March 31, trading up to 1.5c, a 50% lift on the previous close with more than 68m shares changing hands.
The quarterly demonstrated continued progress in advancing the flagship Great White Project in South Australia including considerable project funding progress for the initial Stage 1A+ development.
Importantly, ADN entered into exclusive negotiations for a debt project financing facility with Merricks Capital with a limit of up to A$75 million while due diligence is being carried out by a select number of capital providers.
The negotiations with Merricks Capital are for a debt facility to support a final investment decision for the Stage 1A+ development of 100,000wmtpa.
Both parties are in the final phases of due diligence and negotiations towards agreeing terms and conditions, and securing final approvals for the financing to support a final investment decision for Stage 1A+.
Operationally, during the March quarter the procurement of long-lead items for Stage 1A progressed, with the majority of these items now fabricated and warehoused, ready for shipment to site.
Significant operational planning and project readiness activities are underway to support efficient delivery of Stage 1A+.
On the exploration front, drilling started at the Chairlift deposit to test for potential extensions and better define the high brightness, low titanium portions of the deposit.
The development ready project has most of the pieces needed to proceed with the first stage. It has an ore reserve of 15.1Mt that is sufficient to support a 28-year mine life and a bankable feasibility study estimating it could generate a net present value and internal rate of return of $763m and 43% respectively.
Capex is estimated at $194m for a three-stage development that can supply up to 330,000 wet metric tonnes of product per annum.
'The quarter saw significant progress with our Stage 1A+ funding process, with the entry into exclusive negotiations with Merricks Capital for a debt financing facility following detailed due diligence,' Andromeda's acting CEO Sarah Clarke said.
'The Great White Project is in the enviable position of being development-ready, with all key approvals secured to commence construction.
'In anticipation of a final investment decision for the Great White Project, the company continues to make steady progress in its Stage 1A+ project funding process and operational readiness planning.'
Alkane Resources (ASX:ALK)
Investors in Alkane Resources continue to show their support for the company's merger arrangements with Mandalay Resources with shares rising another 10.26% to 86c, a new high of almost two years.
Alkane, which owns the Tomingley gold mine in New South Wales, and Mandalay Resources, which owns the Costerfield gold and antimony mine in Victoria and Björkdal gold mine in Sweden, announced the merger of equals on Monday.
This combination will create a pro-forma $1.013bn gold producer with a primary Aussie listing as gold prices bounce along at a near record price of US$3300/oz.
The combined entity will have a pro-forma production profile of 160,000ozpa gold equivalent rising to 180,000ozpa from 2026, with $188m of combined cash in the bank.
Each of the Tomingley, Björkdal and Costerfield assets all have opportunities to extend their lives and expand their production profiles via exploration and infrastructure developments.
'The transaction will take Alkane to a new level, bringing together two companies with complementary assets and a shared vision for growth,' Alkane's managing director Nic Earner said.
'Mandalay's two high-quality mines match the attributes of Tomingley: a proven history of consistent production, cash generation and exploration upside.
'The combination of assets, leadership and supportive long-term shareholders enhances our scale and financial strength, and positions us well to continue to pursue additional growth opportunities.'
'We are excited to have found a like-minded partner committed to the same principles.'
Narryer Metals (ASX:NYM)
Another small cap mover is Narryer Metals, which has increased 35.48% to a daily high of 4.2c.
On April 17 the company was buoyed by farm-in partner Petratherm completing phase 2 drilling aimed at testing for extensions of the titanium-rich Rosewood discovery and other titanium prospects at the Muckanippie heavy minerals project in South Australia.
There were 128 holes completed for 4486m to extend Rosewood where highly encouraging heavy mineral intersections were previously recorded over a continuous 15km2 area which remains open in multiple directions.
Initial mineralogy results from the east Rosewood area had indicated HM sands with >95% valuable HM content, composed primarily of high-value titanium minerals – rutile product (high-titanium leucoxene and rutile) and pseudorutile.
Petratherm's (ASX:PTR) drilling also targeted the Duke, Nardoo and Claypan prospects that host a new style of high-grade titanium-rich HM mineralisation in saprolite clay.
The company drilled 73 holes at Rosewood across a 9km east-west trend, extending multiple north-south lines to the north up to 1.6km.
PTR has advised Narryer that it has met the Stage 1 farm-in commitment, earning it a 51% interest in EL 6715 and has also advised that it intends to earn a further 19% interest in the tenement to 70% by spending a further $300,000 over the next 24 months.
Exploration drilling is expected to resume in early June to test for further extensions of the Rosewood mineralisation, particularly to the north.
Dateline Resources (ASX:DTR)
With a bankable feasibility study underway at the 1.1Moz Colosseum Gold Project in California, USA, Dateline Resources has lifted by as much as 43% to 1c.
The BFS is based on open pit mining of the north and south pipes at the Colosseum and processing at a rate of 2Mtpa to produce ~75,000oz per annum over 8.5 years.
BFS parameters align with scenario 2 (open pit only) of a scoping study released in October 2024, which demonstrated an NPV6.5 of US$235 million and IRR of 31% when using a gold price of US$2,200oz.
The scoping study applied a US$2,200 per ounce gold price and the prevailing price is above US$3,300 per ounce, which represents considerable upside.
DTR's BFS, which is expected by the end of 2025, will determine the potential to expand the overall size of the pits to increase the mine life.
Assuming a positive outcome and that finance can be secured for the development, the company hopes to progress to a Final Investment Decision and construction soon after completion of the BFS.
Colosseum is in the Walker Lane Trend in East San Bernardino County, California, and has a JORC-2012 compliant resource estimate of 27.1Mt at 1.26g/t Au for 1.1Moz.
Of the total resource, 455,000oz at 1.47/t (41%) are classified as measured, 281,000oz at 1.21g/t (26%) as indicated and 364,000oz at 1.10g/t (33%) as Inferred.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
an hour ago
- Perth Now
Popular online retailer opening two Perth stores
Online cosmetics retailer Adore Beauty is ramping up its bet on bricks-and-mortar by opening two stores in Perth just weeks apart. Adore will open the 180sqm store in Westfield Carousel on Thursday, with the second location at Booragoon — slightly bigger at 189sqm — coming two weeks later on July 10. It marks Adore's first venture outside its home State of Victoria, where it opened two shopfronts in Southland and Watergardens earlier this year. Adore chief executive Sacha Laing said WA was its fastest growing market in terms of sales. He teased of at least two more stores in Perth over the next 18 months. 'WA was a focus for us, particularly given the speed of the growth in that market,' Mr Laing told The West Australian when asked why Perth beat Sydney. Adore opens its first Sydney store in August. 'When I had the opportunity to secure two locations in the Westfield centres in Booragoon and Carousel, I was like, 'Great, Perth will be our next market that we open in'.' Adore opened its first retail store this month at Westfield Southland. Credit: Supplied The ASX-listed retailer launched as online-only in 2000 and last November first unveiled plans to open more than 25 stores in the next three years. Mr Laing said it was on track to have 20 stores nationally by the end of 2026 after penning deals with 'several of the country's largest landlords'. He is confident about Adore's push into bricks-and-mortar despite social media platforms, like TikTok, becoming an increasingly popular storefront, especially for young consumers. 'In Australia, only 13 per cent of retail sales in the beauty category are done online, so 87 per cent of retail sales in the beauty category are done in physical stores,' Mr Laing said. 'When we look at the opportunity to grow the Adore network . . . there's this huge market that we haven't previously addressed.' Adore Beauty chief executive Sacha Laing at the Watergardens store in Melbourne. Credit: Nicole Squelch While Adore has more than 14,000 products available across 300 brands online, customers will be offered a smaller, curated selection from about 90 brands at Carousel and Booragoon. But for customers who are after a product that is out of stock or only available online, the store's digital kiosk — or what Adore calls the endless aisle — will allow them to pay for it in-store and delivered to their homes. Mr Laing said the stores were deeply immersed in digital, meaning it will mostly be paperless, with screens displaying product descriptions and prices on shelves. '(Being digitally-led enables Adore to) expand ranges really quickly,' he said. 'We could double the size of a brand overnight if we wanted to. We could double the size of a category overnight if we wanted to.' The Perth stores will also offer in-store treatments and dermal therapists. Adore's physical stores are set to challenge major industry players Mecca — which holds the biggest market share in cosmetics in Australia at about 21 per cent — and Sephora, the beauty chain owned by French luxury goods giant LVMH. Sephora and Mecca already have stores in Carousel, with the latter also in Booragoon. According to IBISWorld, Australia's $6 billion cosmetics industry is forecast to grow 2.5 per cent over the next five years. Mr Laing reckons the market is 'big enough for us all'. 'Our product mix and our category mix are quite different. When we think about the competitive set or the overall landscape, there's department stores, there's the value offerings of some of the other mass market beauty retailers, and there's specialty beauty retailers . . . but the market is quite fragmented and what that enables us to do is find our own space,' he said. Adore — founded by Kate Morris — reported revenue of $195.7 million in the 2024 financial year, with net profit hitting $2.2m. That compared with a loss of $559,000 the prior year. Meanwhile, Mecca's latest accounts released earlier this month revealed it had raked in just over $1.2b in revenue in the year to the end of December 2023, up from the $971.5m recorded the previous year. Adore has had a troubled life on the Australian Securities Exchange, with its share price tumbling since listing in October 2020 from $6.91 to 64¢ on Tuesday. Asked if he watched the share price, Mr Laing said 'absolutely'. 'My job is to create shareholder value and to attract new investment interest in the business as well,' he said. 'Acquiring new customers through our online channels and through our physical stores, improving the frequency of new customers and growing the overall revenue line of the business, will inevitably create great profit growth. 'Growing profitability, fundamentally, is what will drive the share price.' Mr Laing took on the top job at Adore last September, replacing Tamalin Morton. He has more than 25 years of experience in the retail industry, having held executive roles at David Jones and Country Road Group. He also led youth fashion retailer General Pants Co and accessory brand Colette by Colette Hayman, which was saved from administration early last year. The reporter travelled to Melbourne as a guest of Adore Beauty.
News.com.au
an hour ago
- News.com.au
Health Check: Imugene goes to the well after reporting more blood cancer ‘cures'
Imugene reports two more 'complete responders' in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk Compumedics shares vault 24% after full-year update Imugene (ASX:IMU) will forge ahead with a planned pivotal US trial for its blood cancer therapy Azer-cel, having recorded more 'complete responses' in its phase 1b study. There's also the matter of cash, with Imugene shares this morning entering trading halt amidst a capital raising reportedly targeting $35 million. The trial is testing the company's CD-19 Car-T therapy on patients with relapsed diffuse large B-cell lymphoma. This is an especially aggressive blood cancer and these patients have failed multiple therapies. The company reports that of five further patients evaluated, two showed a 'complete response'. A complete response is the disappearance of all cancer signs – a.k.a. a cure. A further five showed a 'partial response' – at least a 50% cancer cell reduction. This takes the total number of complete responses to six and partial responses to three, out of 12 patients. The effect has endured for at least 60 days, with the first patient treated remaining cancer free at the 15-month mark. 'Allo 'allo, we're on to something If approved, Azer-cel would be the first off-the-shelf Car-T therapy using donor cells rather than the patients' own material. This is the allogeneic (allo), as opposed to autologous, method. Car-T therapies involve taking T-cells out of blood and tricking them up with agents that bolster their cancer-busting abilities. They are then re-introduced into the bloodstream. The re-engineered cells pursue a target, in this case the CD-19 protein expressed by blood cancers. Next stop: FDA The ongoing study is being carried out at 13 US sites and the first of five planned local sites. The company in February treated the first Australian participant, at Sydney's Royal Prince Alfred Hospital. The subjects were dosed with Azercel, combined alongside chemotherapy and the immunity agent interleukin 2. Imugene plans to meet with the US Food & Drug Administration (FDA) in the December quarter, to discuss a pivotal registration study. As of the end of March, Imugene held cash of $36 million. Drug development is hideously expensive and the last raising is never the final one, and what better time to go to the well than after positive clinical results? Imugene raised $53 million in 2023 and $80 million in 2020 and this year entered into a $20 million convertible note issue. Imugene shares have lost 68% year to date, adjusting for a share consolidation that reduced its 7.46 billion shares on issue to a more respectable 219 million. Clever Culture bulks up with fat-busting drug maker Clever Culture Systems (ASX:CC5) has signed up Big Pharma Novo Nordisk for one of its automated agar plate reading devices to monitor ultra-clean drug making facilities. The maker of the weight loss and diabetes drugs Ozempic and Wegovy, Novo Nordisk will acquire and appraise one of Clever Culture's AI-enabled device APAS Independence units, in view of a full global rollout across its facilities. The AI-enabled APAS Independence devices automatically read the hundreds of agar plates required to ensure that pathogens don't enter aseptic facilities. The units can manage 200 plates per hour, freeing up microbiologists to focus on the minority of plates that read positive. To date Clever Culture has focused on 90 millimetre 'settle' plates that are left open, to absorb any nasties in the room. A tweaked APAS also will read 55mm 'contact' plates, which are dabbed on surfaces, such as a gown or gloved fingertips. Nova Nordisk will assess both settle and contact plate modules. Courting Big Pharma Clever Culture CEO Brent Barnes says the 'milestone' deal aligns with the company's focus on the big drug makers, most of which have centres to appraise new products. To date Clever Culture also sold the devices to Astrazeneca, Bristol Myers Squibb and Thermo Fisher Pharma Services, while a fifth drug maker recently completed a 'successful evaluation'. The five drug makers on the books represent a sales opportunity of between 60 to 80 units. At last count the company had 13 APAS devices in the field, with foundation client Astrazeneca accounting for nine of them. The company cites a 'pipeline' of 40 customers, representing upfront revenue of about $75 million and $15 million of recurring revenue. The APAS unit sells for US$350,000, but Clever Culture then derives ongoing income from an annual software licence of US$30,000 (rising to US$50,000 with the contact plate modality). There's also an annual hardware maintenance fee of $US15,000-25,000. The FDA approved APAS Independence in May 2019 and European regulators followed suit in September 2021. There's no snoozing at Compumedics Sleep and neurological testing house Compumedics (ASX:CMP) has reported record revenue of $51 million for the year to June 2025, up 4%. What's more, the company has returned to profitability, with underlying earnings of $3 million. Compumedics also reports record sales orders of $63.4 million, up 22%. The key driving force was the growth of the US sleep diagnostics arm, up 39% to $53 million. The company also affirmed current year guidance of revenue of at least $70 million and underlying earnings of around $9 million. 'This result reflects the step-change underway at Compumedics,' founder and executive chairman Dr David Burton says. "We are building a more predictable, higher-margin business model and seeing consistent revenue growth, expanding margins and meaningful traction in the US." Proteomics ain't horsing around In time for the spring racing season, Proteomics International Laboratories (ASX:PIQ) says its oxidative stress test Oxidx can detect muscle damage in thoroughbreds. As published in the peer-reviewed journal Veterinary Medicine and Science, the 'groundbreaking' results show Oxidx can identify and assess recovery from exercise-induced damage. The study was based on 34 nags. The company says up to 85% of thoroughbreds sustain at least one injury during their racing seasons, potentially because of undetected muscle injuries. 'Oxidative stress has been implicated in many disease and injury states, with levels often reflective of a person or animal's health condition.' Via its 66% owned OxiDx Pty Ltd, Proteomics plans to launch Oxidx locally in the current half. Proteomics has a commercialised diabetic kidney disease diagnosis and plans to launch an endometriosis assay locally in the current quarter. No pay, no worries says Pacific Edge Pacific Edge (ASX:PEB) reports resilient demand for its bladder cancer diagnostic in the US, despite authorities withdrawing reimbursement coverage. The Kiwi-based company said US June quarter test volumes declined 12% to 5717, relative to the March quarter. Asia Pacific volumes – including those derived here – rose 8.8% to 1183. The company attributed the decline mainly to customers moving to its Cxbladder Triage product, from the discontinued Cxbladder Detect. Cxbladder Triage tests accounted for 77% of total US assays, up from 22% in the March quarter. Pacific Edge also said it had held positive discussions with Novitas, its US Medicare gatekeeper, about reinstating coverage. This was 'based on evidence not considered in the review that led to the non-coverage decision.'
Herald Sun
an hour ago
- Herald Sun
Break it Down: DY6 Metals secures $4.6M to supercharge Cameroon drilling
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Stockhead's Break it Down brings you today's leading market news in under 90 seconds. In this episode, host Tylah Tully takes a look at DY6 Metals (ASX:DY6), which has appointed a new CEO and secured $4.625 million in funding to fast-track exploration at its Central Rutile and Douala Basin Projects in Cameroon. Tune in to hear all about it. While DY6 Metals is a Stockhead advertiser, it did not sponsor this content. Originally published as Break it Down: DY6 Metals secures $4.6M to supercharge Cameroon drilling Stockhead Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive news. Stockhead The S&P/ASX 200 is lower to start the week, dropping 14.40 points or 0.17% to 8565.70 points early doors.
